Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SODIUM DIVALPROATE
DIVALPROATE · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SODIUM DIVALPROATE | DRUG | - |
Inclusion Criteria: * Adolescent boys or girls aged 13 to 18 inclusive * Weighing more than 40 kg * Capable of understanding the protocol * Who have given their written consent, as have their parents or legal guardian unless the adolescent has passed his/her 18th birthday * Presenting the diagnosti...
Top 10 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Xanomeline and trospium chloride, Xanomeline/Trospium Chloride |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Cariprazine, ABBV-932, Icalcaprant |
| Xenon Pharmaceuticals Inc. | XENE | 2 | PHASE3 | Azetukalner |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Rapport Therapeutics, Inc. | RAPP | 1 | PHASE2 | RAP-219 |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE2 | NBI-1117568 |
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-100 |
| LB Pharmaceuticals, Inc. | LBRX | 1 | PHASE2 | LB-102 |
| BioXcel Therapeutics, Inc. | BTAI | 1 | PHASE1 | BXCL501 |
| Alzamend Neuro, Inc. | ALZN | 1 | PHASE1 | AL001 |
Divalproate is being studied for the treatment of bipolar disorder. It is a small molecule therapy in Phase 3 clinical development. The clinical program has focused on evaluating its use in adolescents with bipolar disorder, with a completed Phase 3 safety study conducted in France.
Divalproate is developed by Sanofi, which trades under the ticker SNY. Sanofi is the company responsible for the clinical development of divalproate in bipolar disorder.
Divalproate is in Phase 3 clinical development for bipolar disorder. It is an investigational therapy and has not been approved by the FDA for this indication based on the available information. The Phase 3 program includes one completed trial.
Divalproate has been evaluated in one Phase 3 clinical trial, NCT00271258, titled Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents. The trial was completed, enrolled 200 participants, and was conducted in France. It was an uncontrolled study without randomization or double blinding.
Yes, divalproate is also known as sodium divalproate. The two names refer to the same small molecule therapeutic being developed by Sanofi for bipolar disorder. Searches for either name refer to the same investigational asset.